MGI Pharma maintained at market perform by JMP

JMP Securities analyst Charles C. Duncan kept MGI Pharma, Inc. at its market perform rating on news the company signed a licensing agreement with Janssen-Cilag for the ex-North America rights to develop and commercialize Dacogen for the treatment of myelodysplastic syndrome. The deals add what the analyst believes is incremental value to the company, putting the global deal in the "nice to have" category. Shares of the Bloomington, Minn.-based biopharmaceutical company were down 9 cents, or 0.43%, at $20.97 on volume of 383,947 shares versus the three-month running average of 1,143,230 shares. (Nasdaq: MOGN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.